The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
4-Arylazo-3,5-diamino-1 H-pyrazole CDK Inhibitors: SAR Study, Crystal Structure in Complex with CDK2, Selectivity, and Cellular Effects
Open accessAbstract
In a routine screening of our small-molecule compound collection we recently identified 4-arylazo-3,5-diamino-1H-pyrazoles as a novel group of ATP antagonists with moderate potency against CDK2-cyclin E. A preliminary SAR study based on 35 analogues suggests ways in which the pharmacophore could be further optimized, for example, via substitutions in the 4-aryl ring. Enzyme kinetics studies with the lead compound and X-ray crystallography of an inhibitor-CDK2 complex demonstrated that its mode of inhibition is competitive. Functional kinase assays confirmed the selectivity toward CDKs, with a preference for CDK9-cyclin T1. The most potent inhibitor, 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol 31b (CAN508), reduced the frequency of S-phase cells of the cancer cell line HT-29 in antiproliferation assays. Further observed cellular effects included decreased phosphorylation of the retinoblastoma protein and the C-terminal domain of RNA polymerase II, inhibition of mRNA synthesis, and induction of the tumor suppressor protein p53, all of which are consistent with inhibition of CDK9.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
The specificities of protein kinase inhibitors: an update
BAIN, J., McLAUCHLAN, H., ELLIOTT, M., & COHEN, P. (2003) · Biochemical Journal · doi:10.1042/bj20021535 · Cited by 1,369
Cited by
Review: biologically active pyrazole derivatives
Ansari, A., Ali, A., Asif, M., & Shamsuzzaman, S. (2017) · New Journal of Chemistry · doi:10.1039/c6nj03181a · Cited by 786
Molegro Virtual Docker for Docking
Bitencourt-Ferreira, G., & de Azevedo, W. F. (2019) · Methods in Molecular Biology · doi:10.1007/978-1-4939-9752-7_10 · Cited by 331
Self-citation
Metadata
- Authors
- Kryštof, V., Cankař, P., Fryšová, I., Slouka, J., Kontopidis, G., Džubák, P., Hajdúch, M., Srovnal, J., de Azevedo, W. F., Orság, M., Paprskářová, M., Rolčík, J., Látr, A., Fischer, P. M., & Strnad, M.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2006-09-29
- Volume
- 49
- Issue
- 22
- Pages
- 6500-6509
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W1982308040
- Cited by
- 194
- References
- 2
- FWCI
- 1.99
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 4-Arylazo-3,5-diamino-1 H-pyrazole CDK Inhibitors: SAR Study, Crystal Structure in Complex with CDK2, Selectivity, and Cellular Effects. https://app.cochat.ai/papers/10.1021/jm0605740
- The paper
- Kryštof, V., Cankař, P., Fryšová, I., Slouka, J., Kontopidis, G., Džubák, P., Hajdúch, M., Srovnal, J., de Azevedo, W. F., Orság, M., Paprskářová, M., Rolčík, J., Látr, A., Fischer, P. M., & Strnad, M. (2006). 4-Arylazo-3,5-diamino-1 H-pyrazole CDK Inhibitors: SAR Study, Crystal Structure in Complex with CDK2, Selectivity, and Cellular Effects. Journal of Medicinal Chemistry. https://doi.org/10.1021/jm0605740
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.